Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- RVTY +4.7%, CX +2.7%, BKU +1%
Other news:
- CGON +39.5% (Announces Best-in-Disease Durability Data in BOND-003 Cohort C)
- NN +15.7% (files for 22,927,380 shares of common stock offering by selling shareholders; relates to warrants)
- AMPY +8.9% (Amplify Energy and Juniper Capital announce termination of merger agreement)
- RVMD +5.8% (Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting)
- SNTI +5.8% (reports additional positive preliminary data from a Phase 1 clinical trial of SENTI-202)
- URGN +5.5% (reports Phase 1 study evaluating UGN-301 in non-muscle invasive bladder cancer; Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102)
- SPIR +4.8% (completes previously announced sale of its maritime business to Kpler for $233.5 mln; used proceeds to retire all outstanding debt)
- ETON +3.9% (announces submission of NDA for ET-600)
- ADCT +3.8% (Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025)
- RDHL +3.3% (announces that the China National Intellectual Property Administration has formally allowed a critical use of composition-of-matter patent for RedHill's proprietary investigational compound RHB-107)
- ADMA +3.2% (FDA approval of its innovative yield enhancement production process)
- SWTX +3% (to be acquired by Merck KGaA (MKKGY) for $47.00 per share)
- TM +2.7% (responds to media reports)
- SPR +2.5% (enters divestiture agreement with Airbus)
- FFAI +2.4% (receives endorsements from California politicians supporting FF's Global Automotive Bridge Strategy)
- CADE +1.7% (authorizes a new repurchase plan for up to 10 mln shares; to acquire Industry Bancshares)
- NIO +1.7% (battery expansion has stalled in Europe, according to Electric Vehicles.com)
- TARA +1.6% (Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC)
- BA +1.6% (Riyadh Air could purchase BA jets rejected by China, according to Reuters)
- BBIO +1.5% (reprots BEYONTTRA approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM)
- BERY +1.1% (Amcor and Berry Global Group (BERY) announce the European Commission has granted unconditional approval under the EU Merger Regulation for the previously announced combination of the two companies)